keyword
MENU ▼
Read by QxMD icon Read
search

"RSV vaccine"

keyword
https://www.readbyqxmd.com/read/29327237/regional-age-and-respiratory-secretion-specific-prevalence-of-respiratory-viruses-associated-with-asthma-exacerbation-a-literature-review
#1
REVIEW
Xue-Yan Zheng, Yan-Jun Xu, Wei-Jie Guan, Li-Feng Lin
Despite increased understanding of how viral infection is involved in asthma exacerbations, it is less clear which viruses are involved and to what extent they contribute to asthma exacerbations. Here, we sought to determine the prevalence of different respiratory viruses during asthma exacerbations. Systematic computerized searches of the literature up to June 2017 without language limitation were performed. The primary focus was on the prevalence of respiratory viruses, including AdV (adenovirus), BoV (bocavirus), CoV (coronavirus), CMV (cytomegalovirus), EnV (enterovirus), HSV (herpes simplex virus), IfV (influenza virus), MpV (metapneumovirus), PiV (parainfluenzavirus), RV (rhinovirus) and RSV (respiratory syncytial virus) during asthma exacerbations...
January 11, 2018: Archives of Virology
https://www.readbyqxmd.com/read/29234123/dusp1-regulates-apoptosis-and-cell-migration-but-not-the-jip1-protected-cytokine-response-during-respiratory-syncytial-virus-and-sendai-virus-infection
#2
Alexa C Robitaille, Elise Caron, Nicolas Zucchini, Espérance Mukawera, Damien Adam, Mélissa K Mariani, Anaïs Gélinas, Audray Fortin, Emmanuelle Brochiero, Nathalie Grandvaux
The host antiviral response involves the induction of interferons and proinflammatory cytokines, but also the activation of cell death pathways, including apoptosis, to limit viral replication and spreading. This host defense is strictly regulated to eliminate the infection while limiting tissue damage that is associated with virus pathogenesis. Post-translational modifications, most notably phosphorylation, are key regulators of the antiviral defense implying an important role of protein phosphatases. Here, we investigated the role of the dual-specificity phosphatase 1 (DUSP1) in the host defense against human respiratory syncytial virus (RSV), a pathogenic virus of the Pneumoviridae family, and Sendai virus (SeV), a model virus being developed as a vector for anti-RSV vaccine...
December 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29187732/structural-basis-of-respiratory-syncytial-virus-subtype-dependent-neutralization-by-an-antibody-targeting-the-fusion-glycoprotein
#3
Daiyin Tian, Michael B Battles, Syed M Moin, Man Chen, Kayvon Modjarrad, Azad Kumar, Masaru Kanekiyo, Kevin W Graepel, Noor M Taher, Anne L Hotard, Martin L Moore, Min Zhao, Zi-Zheng Zheng, Ning-Shao Xia, Jason S McLellan, Barney S Graham
A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. Here we show that unlike D25, 5C4 preferentially neutralizes subtype A viruses. The crystal structure of 5C4 bound to the RSV fusion (F) protein reveals that the overall binding mode of 5C4 is similar to that of D25, but their angles of approach are substantially different...
November 30, 2017: Nature Communications
https://www.readbyqxmd.com/read/29172458/transiently-thermoresponsive-acetal-polymers-for-safe-and-effective-administration-of-amphotericin-b-as-vaccine-adjuvant
#4
Simon Van Herck, Lien Van Hoecke, Benoit Louage, Lien Lybaert, Ruben De Coen, Sabah Kasmi, Aaron P Esser-Kahn, Sunil A David, Lutz Nuhn, Bert Schepens, Xavier Saelens, Bruno G De Geest
The quest for new potent and safe adjuvants to skew and boost the immune response of vaccines against intracellular pathogens and cancer has led to the discovery of a series of small molecules that can activate Toll like receptors (TLRs). Whereas many small molecule TLR agonists cope with a problematic safety profile, Amphotericin B (AmpB) - an FDA-approved anti-fungal drug - has recently been discovered to possess TLR triggering activity. However, its poor aqueous solubility and cytotoxicity at elevated concentrations currently hampers its development as a vaccine adjuvant...
November 26, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/29121080/respiratory-syncytial-virus-elicits-enriched-cd8-t-lymphocyte-responses-in-lung-compared-with-blood-in-african-green-monkeys
#5
COMPARATIVE STUDY
Hualin Li, Cheryl Callahan, Michael Citron, Zhiyun Wen, Sinoeun Touch, Morgan A Monslow, Kara S Cox, Daniel J DiStefano, Kalpit A Vora, Andrew Bett, Amy Espeseth
Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in young children and older adults throughout the world. Prevention of severe RSV disease through active immunization is optimal but no RSV vaccine has been licensed so far. Immune mechanisms of protection against RSV infection in humans have not been fully established, thus a comprehensive characterization of virus-specific immune responses in a relevant animal model will be beneficial in defining correlates of protection...
2017: PloS One
https://www.readbyqxmd.com/read/29118126/respiratory-syncytial-virus-rsv-targeting-the-g-protein-provides-a-new-approach-for-an-old-problem
#6
Ralph A Tripp, Ultan F Power, Peter J M Openshaw, Lawrence M Kauvar
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection (LRTI) annually affecting >2 million children in the US <5 years old. In the elderly (>65 years old), RSV results in ∼175,000 hospitalizations annually in the US with worldwide incidence ∼34 million. There is no approved RSV vaccine and treatments are limited. Recently, a Phase 3 trial in the elderly using a recombinant RSV F protein vaccine failed to meet its efficacy objectives, namely prevention of moderate-to-severe RSV-associated LRTI and reduced incidence of acute respiratory disease...
November 8, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29112722/on-the-relative-role-of-different-age-groups-during-epidemics-associated-with-respiratory-syncytial-virus
#7
Edward Goldstein, Hieu H Nguyen, Patrick Liu, Cecile Viboud, Claudia A Steiner, Colin J Worby, Marc Lipsitch
Background: While circulation of respiratory syncytial virus (RSV) results in high rates of hospitalization, particularly among young children and the elderly, little is known about the role of different age groups in propagating annual RSV epidemics. Methods: We evaluate the roles played by individuals in different age groups during RSV epidemics in the US between 2001-2012 using the previously defined relative risk (RR) statistic estimated for hospitalization data from the Healthcare Cost and Utilization Project (HCUP)...
November 3, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29076066/recombinant-baculovirus-based-vaccine-expressing-m2-protein-induces-protective-cd8-t-cell-immunity-against-respiratory-syncytial-virus-infection
#8
Jeong-Yoon Lee, Jun Chang
Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory tract disease in infants, young children, immunocompromised individuals, and the elderly. However, despite ongoing efforts to develop an RSV vaccine, there is still no authorized RSV vaccine for humans. Baculovirus has attracted attention as a vaccine vector because of its ability to induce a high level of humoral and cellular immunity, low cytotoxicity against various antigens, and biological safety for humans. In this study, we constructed a recombinant baculovirus- based vaccine expressing the M2 protein of RSV under the control of cytomegalovirus promoter (Bac_RSVM2) to induce CD8(+) T-cell responses which play an important role in viral clearance, and investigated its protective efficacy against RSV infection...
November 2017: Journal of Microbiology / the Microbiological Society of Korea
https://www.readbyqxmd.com/read/29057917/pre-fusion-rsv-f-strongly-boosts-pre-fusion-specific-neutralizing-responses-in-cattle-pre-exposed-to-bovine-rsv
#9
Ann-Muriel Steff, James Monroe, Kristian Friedrich, Sumana Chandramouli, Thi Lien-Anh Nguyen, Sai Tian, Sarah Vandepaer, Jean-François Toussaint, Andrea Carfi
Human respiratory syncytial virus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older adults, and remains an important vaccine need. RSV fusion (F) glycoprotein is a key target for neutralizing antibodies. RSV F stabilized in its pre-fusion conformation (DS-Cav1 F) induces high neutralizing antibody titers in naïve animals, but it remains unknown to what extent pre-fusion F can boost pre-existing neutralizing responses in RSV seropositive adults. We here assess DS-Cav1 F immunogenicity in seropositive cattle pre-exposed to bovine RSV, a virus closely related to hRSV...
October 20, 2017: Nature Communications
https://www.readbyqxmd.com/read/29029260/an-adjuvanted-postfusion-f-protein-based-vaccine-did-not-prevent-respiratory-syncytial-virus-illness-in-older-adults
#10
RANDOMIZED CONTROLLED TRIAL
Judith Falloon, Jing Yu, Mark T Esser, Tonya Villafana, Li Yu, Filip Dubovsky, Therese Takas, Myron J Levin, Ann R Falsey
Background: Respiratory syncytial virus (RSV) is an important cause of illness in older adults. This study assessed efficacy of a vaccine for prevention of RSV-associated acute respiratory illness (ARI), defined by specified symptoms with virologic confirmation. Methods: This phase 2b study evaluated RSV postfusion F protein (120 µg) with glucopyranosyl lipid adjuvant (5 µg) in 2% stable emulsion. Subjects aged ≥60 years were randomly assigned at a ratio of 1:1 to receive vaccine or placebo (all received inactivated influenza vaccine)...
December 12, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29021918/protection-of-calves-by-a-prefusion-stabilized-bovine-rsv-f-vaccine
#11
Baoshan Zhang, Lei Chen, Chiara Silacci, Michelle Thom, Jeffrey C Boyington, Aliaksandr Druz, M Gordon Joyce, Efrain Guzman, Wing-Pui Kong, Yen-Ting Lai, Guillaume B E Stewart-Jones, Yaroslav Tsybovsky, Yongping Yang, Tongqing Zhou, Ulrich Baxa, John R Mascola, Davide Corti, Antonio Lanzavecchia, Geraldine Taylor, Peter D Kwong
Bovine respiratory syncytial virus, a major cause of respiratory disease in calves, is closely related to human RSV, a leading cause of respiratory disease in infants. Recently, promising human RSV-vaccine candidates have been engineered that stabilize the metastable fusion (F) glycoprotein in its prefusion state; however, the absence of a relevant animal model for human RSV has complicated assessment of these vaccine candidates. Here, we use a combination of structure-based design, antigenic characterization, and X-ray crystallography to translate human RSV F stabilization into the bovine context...
March 8, 2017: NPJ Vaccines
https://www.readbyqxmd.com/read/28988544/molecular-and-clinical-characterization-of-human-respiratory-syncytial-virus-in-south-korea-between-2009-and-2014
#12
E Park, P H Park, J W Huh, H J Yun, H K Lee, M H Yoon, S Lee, G Ko
Respiratory syncytial virus (RSV) can cause serious respiratory infections, second only to influenza virus. In order to know RSV's genetic changes we examined 4028 respiratory specimens from local hospital outpatients in Gyeonggi Province, South Korea over six consecutive years by real-time one-step RT-PCR; 183 patients were positive for RSV infection. To investigate the specific distribution of RSV genotypes, we performed partial sequencing of the glycoprotein gene. Of the 131 RSV-A specimens sequenced, 61 (43·3%) belonged to the ON1 genotype, 66 (46·8%) were NA1 genotype, 3 (2·1%) were GA5 genotype, and 1 (0·7%) belonged to the GA1 genotype...
November 2017: Epidemiology and Infection
https://www.readbyqxmd.com/read/28967522/potential-impact-of-a-maternal-vaccine-for-rsv-a-mathematical-modelling-study
#13
Alexandra B Hogan, Patricia T Campbell, Christopher C Blyth, Faye J Lim, Parveen Fathima, Stephanie Davis, Hannah C Moore, Kathryn Glass
Respiratory syncytial virus (RSV) is a major cause of respiratory morbidity and one of the main causes of hospitalisation in young children. While there is currently no licensed vaccine for RSV, a vaccine candidate for pregnant women is undergoing phase 3 trials. We developed a compartmental age-structured model for RSV transmission, validated using linked laboratory-confirmed RSV hospitalisation records for metropolitan Western Australia. We adapted the model to incorporate a maternal RSV vaccine, and estimated the expected reduction in RSV hospitalisations arising from such a program...
October 27, 2017: Vaccine
https://www.readbyqxmd.com/read/28942341/respiratory-syncytial-virus-hospitalization-in-middle-aged-and-older-adults
#14
Ryan E Malosh, Emily T Martin, Amy P Callear, Joshua G Petrie, Adam S Lauring, Lois Lamerato, Alicia M Fry, Jill Ferdinands, Brendan Flannery, Arnold S Monto
BACKGROUND: The importance of Respiratory Syncytial Virus (RSV) is increasingly recognized in hospitalized adults, but mainly in those ≥ 65 years. OBJECTIVES: We sought to describe the epidemiology and clinical severity of RSV compared to influenza in hospitalized adults ≥18 years. STUDY DESIGN: Adults hospitalized with acute respiratory illnesses (ARI) of ≤10days duration were prospectively enrolled from two Michigan hospitals during two influenza seasons...
September 7, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28933663/type-iii-hypersensitivity-reactions-to-a-b-cell-epitope-antigen-are-abrogated-using-a-depot-forming-vaccine-platform
#15
Lisa D MacDonald, Alecia MacKay, Valarmathy Kaliaperumal, Genevieve Weir, Andrea Penwell, Rajkannan Rajagopalan, Joanne M Langley, Scott Halperin, Marc Mansour, Marianne M Stanford
Peptide antigens are combined with an adjuvant in order to increase immunogenicity in vivo. The immunogenicity and safety of a RSV vaccine formulated in a novel oil-based platform, DepoVax™ (DPX), was compared to an alum formulation. A peptide B cell epitope derived from RSV small hydrophobic ectodomain (SHe) served as the antigen. Both vaccines induced SHe-specific antibodies after immunization of mice. A single dose of the DPX-based formulation resulted in anti-SHe titres for up to 20 weeks. Boosting with Alum-SHe, but not with DPX-SHe, led to unexpected clinical signs such as decreased activity, cyanosis and drop in body temperature in mice but not in rabbits...
September 21, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28903503/identifying-gaps-in-respiratory-syncytial-virus-disease-epidemiology-in-the-united-states-prior-to-the-introduction-of-vaccines
#16
Lindsay Kim, Brian Rha, Jon S Abramson, Larry J Anderson, Carrie L Byington, Grace L Chen, John DeVincenzo, Kathryn M Edwards, Janet A Englund, Ann R Falsey, Marie R Griffin, Ruth A Karron, Karen G Martin, H Cody Meissner, Flor M Munoz, Andrew T Pavia, Pedro A Piedra, William Schaffner, Eric A F Simões, Rosalyn Singleton, H Keipp Talbot, Edward E Walsh, Jane R Zucker, Susan I Gerber
Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations...
September 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28903080/transplacental-transfer-of-maternal-respiratory-syncytial-virus-rsv-antibody-and-protection-against-rsv-disease-in-infants-in-rural-nepal
#17
Helen Y Chu, James Tielsch, Joanne Katz, Amalia S Magaret, Subarna Khatry, Stephen C LeClerq, Laxman Shrestha, Jane Kuypers, Mark C Steinhoff, Janet A Englund
BACKGROUND: Respiratory syncytial virus (RSV) is the most important viral cause of pneumonia in children. RSV-specific antibody (ab) protects infants from disease, and may be increased by a potential strategy of maternal RSV vaccination. OBJECTIVES: To describe the effect of RSV antibody on RSV infection risk in infants in a resource-limited setting. STUDY DESIGN: In a prospective study in Nepal, women were enrolled during pregnancy and maternal and infant cord blood were collected at birth...
October 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28894111/induction-of-high-titred-non-neutralising-antibodies-by-self-adjuvanting-peptide-epitopes-derived-from-the-respiratory-syncytial-virus-fusion-protein
#18
Noushin Jaberolansar, Keith J Chappell, Daniel Watterson, Imogen M Bermingham, Istvan Toth, Paul R Young, Mariusz Skwarczynski
Respiratory syncytial virus (RSV) causes severe lower respiratory tract illness in infants and young children. The significant morbidity and mortality rates associated with RSV infection make an effective RSV vaccine development a priority. Two neutralising antibody binding sites, Ø and II, located on the pre-fusion RSV F glycoprotein are prime candidates for epitope-focused vaccine design. We report on a vaccine strategy that utilises a lipid core peptide (LCP) delivery system with self-adjuvanting properties in conjunction with either the antigenic site Ø or II (B cell epitopes) along with PADRE as a T helper cell epitope...
September 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28881156/nucleic-acid-based-vaccines-targeting-respiratory-syncytial-virus-delivering-the-goods
#19
Trevor R F Smith, Katherine Schultheis, Kate E Broderick
Respiratory syncytial virus (RSV) is a massive medical burden on a global scale. Infants, children and the elderly represent the vulnerable populations. Currently there is no approved vaccine to protect against the disease. Vaccine development has been hindered by several factors including vaccine enhanced disease (VED) associated with formalin-inactivated RSV vaccines, inability of target populations to raise protective immune responses after vaccination or natural viral infection, and a lack of consensus concerning the most appropriate virus-associated target antigen...
November 2, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28865676/determining-the-outcomes-of-interventions-to-prevent-respiratory-syncytial-virus-disease-in-children-what-to-measure
#20
REVIEW
Ruth A Karron, Heather J Zar
Respiratory syncytial virus (RSV) is the most common cause of viral acute lower respiratory tract illness (LRTI) in young children, and a major cause of hospital admissions and health-care utilisation globally. Substantial efforts have been made to develop RSV vaccines and vaccine-like monoclonal antibodies to prevent acute RSV LRTI. Prevention of acute disease could improve long-term lung health, with potential effects on wheezing, asthma, and chronic lung disease. This Personal View describes assessments that should be initiated during clinical trials and continued after licensure to fully evaluate the effect of RSV preventive interventions...
January 2018: Lancet Respiratory Medicine
keyword
keyword
66261
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"